New psoriasis shot shows promise in early trial

NCT ID NCT07090330

Ongoing Disease control Sponsor: Oruka Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either ORKA-001 or a placebo injection, and doctors measure how much skin clears up after 16 weeks. The goal is to see if ORKA-001 is safe and effective enough to move into larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ORKA-001 (injection)

What this could lead to

If successful, ORKA-001 could offer a new treatment option to clear psoriasis skin lesions for people with moderate-to-severe disease.

What could go wrong

This is an early Phase 2 proof-of-concept study with only 80 participants. It may not show enough benefit or could have side effects, and larger trials are needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Show contact details

Locations

Oruka Therapeutics Investigative Site

Fountain Valley, California, 92708, United States
Oruka Therapeutics Investigative Site

Los Angeles, California, 90045, United States
Oruka Therapeutics Investigative Site

San Diego, California, 92123, United States
Oruka Therapeutics Investigative Site

Santa Ana, California, 92701, United States
Oruka Therapeutics Investigative Site

Santa Monica, California, 90403, United States
Oruka Therapeutics Investigative Site

Cromwell, Connecticut, 06416, United States
Oruka Therapeutics Investigative Site

Miami, Florida, 33126, United States
Oruka Therapeutics Investigative Site

Rolling Meadows, Illinois, 60008, United States
Oruka Therapeutics Investigative Site

Bowling Green, Kentucky, 42104, United States
Oruka Therapeutics Investigative Site

Rockville, Maryland, 20850, United States
Oruka Therapeutics Investigative Site

Boston, Massachusetts, 02111, United States
Oruka Therapeutics Investigative Site

Detroit, Michigan, 48202, United States
Oruka Therapeutics Investigative Site

New York, New York, 10023, United States
Oruka Therapeutics Investigative Site

New York, New York, 10029, United States
Oruka Therapeutics Investigative Site

Portland, Oregon, 97201, United States
Oruka Therapeutics Investigative Site

Norfolk, Virginia, 23502, United States
Oruka Therapeutics Investigative Site

Milwaukee, Wisconsin, 53226, United States
Oruka Therapeutics Investigative Site

Edmonton, Alberta, T5J 3S9, Canada
Oruka Therapeutics Investigative Site

Edmonton, Alberta, T6G 1C3, Canada
Oruka Therapeutics Investigative Site

Surrey, British Columbia, V3R 6A7, Canada
Oruka Therapeutics Investigative Site

Hamilton, Ontario, L8N 1Y2, Canada
Oruka Therapeutics Investigative Site

London, Ontario, N6H 5LS, Canada
Oruka Therapeutics Investigative Site

Markham, Ontario, L3P 1X3, Canada
Oruka Therapeutics Investigative Site

Peterborough, Ontario, K9J 5K2, Canada
Oruka Therapeutics Investigative Site

Toronto, Ontario, M4W 2N4, Canada
Oruka Therapeutics Investigative Site

Waterloo, Ontario, N2J 1C4, Canada